BIO-Europe® 2012 Presenting Companies Offer Preview of Market Innovation to VC and Pharma Investors
The 18th annual BIO-Europe® international partnering conference will be held in Hamburg, Germany November 12–14, 2012 at the CCH Congress Center Hamburg. Europe’s largest partnering conference attracts the world’s top dealmakers from biotech, pharma and finance along with exciting emerging companies.
The event, organized by EBD Group, the leading partnering firm for the life science industry, will highlight the biotech and pharmaceutical community in the Hamburg and Schleswig-Holstein life science sector and the BioRegion comprised of Denmark, Estonia, Finland, Iceland, Latvia, Lithuania, Norway, Poland, Sweden, northern Germany and northwestern part of Russia.
The high caliber of the conference program is exemplified by the Monday business development track entitled “New Pharma Strategies: Refining the R&D Blueprint” that features a powerful lineup of experts weighing in on the changing blueprint of R&D and commercialization strategies. The session will be moderated by George Schmidt of Campbell Alliance with panelists Philippe Lopes-Fernandes of Merck Serono; Anders Ekblom of AstraZeneca; and Garry Neil of the newly formed TransCelerate BioPharma collaborative.
“Partnering within R&D is improving discovery productivity and strengthening industry pipelines,” said Anders Ekblom of AstraZeneca. “However, more work is needed to operationalize innovative, collaborative structures among multiple players. Getting this right will benefit not only the entire drug development value chain, but most importantly, patients who need novel drugs.”
The presenting companies portion of the program gives venture capitalists and pharmaceutical companies a firsthand look at prominent new discovery pipelines taking shape in the market.
“Local and international companies are selected based on their innovative technologies and the opportunities available to potential partners. It is this innovation that will lead the future of drug development,” said Carola Schropp , President of EBD Group.
There will be company presentations by emerging biotech companies, and many returning presenters such as 4SC AG; Addex Therapeutics; Ark Therapeutics; Cevec Pharmaceuticals GmbH; Curis Inc.; Medigene AG; and Scil Proteins GmbH.
Another focus of the company presentations is on next generation companies from academic technology transfer and commercialization groups as well as innovative young companies including: Algiax Pharmaceuticals GmbH; DCPrime; GNA Biosolutions; Verapido / HSG-IMIT; Johns Hopkins School of Medicine; Macquarie University; PharmAbcine, Inc; Soluventis; UroTiss GmbH; Ciloa; Delenex Therapeutics AG; Toleranzia AB; STAT-Diagnostica & Innovation; BioScience Slovakia s.r.o.; Acesion Pharma; PSites Pharma GmbH; Novadiscovery; Jagiellonian University; Inositec; and Vaxdyn, SL.
“We develop fully integrated molecular and immunoassay diagnostic systems for clinical applications. Our products will allow the testing and screening of microorganisms, genetic-based diseases, or other analytes in a precise and automated way,” said Jordi Carrera from STAT-Diagnostica. “We are excited to present at BIO-Europe to find new partners that can help us further develop our Near Patient Testing products for healthcare and critical care professionals. BIO-Europe presents an incomparable opportunity for us to reach a large number of potential investors and partners in the smallest amount of time.”
This year’s event is being held in collaboration with Norgenta, known also as “Life Science Nord,” the service agency of Hamburg and the Federal State of Schleswig-Holstein, and ScanBalt™ fmba, the BioRegion association comprised of health and life science based sectors in the Nordic and Baltic countries.
Global networking opportunities can begin before the conference starts by joining partnering360®, the open online network for life science dealmakers at www.partnering360.com . partnering360 helps delegates have a more productive experience leading up to Bio-Europe and will grow their partnering network.
Registration information for BIO-Europe can be found online at http://www.ebdgroup.com/bioeurope/registration/index.php
About EBD Group
EBD Group is the leading partnering firm for the global life science industry. Since 1993, biotech, pharma and medical device companies have leveraged EBD Group’s partnering conferences, technology and services to identify business opportunities and develop strategic relationships essential to their success.
EBD Group’s conferences are run with the support of leading corporations and international trade associations and include:
- BIO-Europe ® and BIO-Europe Spring ®, Europe’s largest life science partnering conferences, supported by the Biotechnology Industry Organization (BIO)
- BioPharm America ™, the fastest growing partnering event in North America
- Biotech Showcase ™, a unique forum in San Francisco for presenting to investors and business development executives, co-produced with Demy-Colton Life Science Advisors
- BioEquity Europe , the investor conference co-organized with BioCentury Publications and BIO
- ChinaBio® Partnering Forum , the first dedicated biotech/pharma partnering conference in China, co-produced with ChinaBio® LLC
- EuroMedtech ™, EBD Group’s partnering event for the innovative medical technology industry
- Partnering for Global Impact ®, a new partnering conference providing an innovative forum to partner, identify and generate social and philanthropic investment and funding opportunities
EBD Group’s sophisticated web-based partnering service, partneringONE®, is also used as the partnering engine at numerous third-party events around the world, and partnering360® is the open online community of life science dealmakers that enhances partnering experiences all year long. Outside of the conference format, EBD Group’s consultants provide hands-on assistance for firms seeking to in- or out-license products and technologies.
EBD Group has offices in the USA and Europe.
For more information please visit www.ebdgroup.com.
* per an article from Current Partnering [dot] com: http://www.currentpartnering.com/2012/07/20/top-partnering-deals-so-far-in-2012/
Contact:
EBD Group
Erin Righetti, +1 760-930-0500
erighetti@ebdgroup.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis16.7.2025 07:00:00 CEST | Press release
- First patient enrolled in INFLAM MOTION, a global randomized Phase 2a trial including 129 knee osteoarthritis patients - 4P004 to be evaluated over 3 months for dual efficacy: symptom relief and synovial health improvement via contrast-enhanced MRI - Topline results expected in the second half of 2026 4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P
Belkin Achieves Qi2.2 Certification for Its Upcoming Products, Unlocking the Future of 25W Wireless Charging15.7.2025 19:06:00 CEST | Press release
With Qi2.2 certification, Belkin reinforces its commitment to quality, safety, and performance for the next generation of wireless charging Belkin, a leading consumer electronics brand for over 40 years, today announced it has received official Qi2.2 certification from the Wireless Power Consortium (WPC) for its upcoming products. As one of the first accessory brands to deliver Qi2.2-certified devices, Belkin is helping bring the next generation of wireless charging to market – enabling faster wireless charging speeds, broader compatibility, and improved performance for consumers. Belkin’s close partnership with the WPC since 2015 has been instrumental in bringing these advancements to consumers. As an early adopter and long-time contributor to WPC standards, Belkin was selected as one of a small group of trusted manufacturers to test and certify Qi2.2 products ahead of the broader industry rollout. All Belkin products undergo rigorous safety, quality, and performance testing. The comp
Cessna Grand Caravan EX to Feature New Executive Interior Options, Expanding Opportunities for Elevated Missions15.7.2025 18:05:00 CEST | Press release
The legendary Cessna Grand Caravan EX will now feature three new executive interior schemes for customers to select when designing their aircraft cabin. The Lunar, Obsidian and Saddle Sport interiors join the existing Canyon and Savanna schemes, providing a broader range of standard choices. The new interior options are available to customers starting this month and allow them to further tailor the interior of their aircraft based on their personal preference or mission. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715021096/en/ Cessna Grand Caravan EX to feature new executive interior options, expanding opportunities for elevated missions (Photo Credit: Textron Aviation) The Cessna Grand Caravan EX is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company. Premium versions of each of the new interiors are also available, featuring quilted seat stitching and plush carpet, providing an elev
7 Million Tokens Sells Out in less than One Hour—$MBG Token Pre-Sale Shatters Expectations15.7.2025 17:27:00 CEST | Press release
MultiBank Group, the world’s largest and most regulated financial derivatives institution, has set a new benchmark in digital asset launches. The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715055611/en/ The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. Commenting on the success of the Pre-Sale, Naser Taher, Founder and Chairman of MultiBank Group, said: “The sell-out of our initial $MBG Token offering in less than one hour is a decisive validation of our vision. In a market saturated with speculation, the response we received confirms that institutional-grade transparency, regulatory integrity, and asset-backed value are what investors are now demanding. $MBG is here for the long term, reflecting t
First Patient Enrolled in National Cancer Institute’s Vanguard Study Evaluating Guardant Health’s Shield Multi-Cancer Detection Test15.7.2025 17:01:00 CEST | Press release
Study addressing feasibility of using multi-cancer detection tests in future trials aims to enroll up to 24,000 participantsShield MCD reviewed by FDA as part of NCI’s investigational device exemption (IDE) Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that patient enrollment has begun in the National Cancer Institute (NCI)’s Vanguard Study to evaluate emerging multi-cancer detection (MCD) technology. Guardant’s Shield™ MCD test was selected for use in the four-year study, which aims to enroll up to 24,000 patients and evaluate the use of MCD tests—blood tests that can screen for several types of cancer simultaneously—in future randomized controlled trials. Guardant’s Shield MCD test was chosen for the study based on the overall performance of its Shield platform in detecting 10 cancer types, including lung, breast, colorectal, prostate, bladder, ovarian, pancreatic, esophageal, liver and gastric. The data were presented at the 2025 American
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom